Nextcure Stock Performance
| NXTC Stock | USD 0.65 0.03 4.84% |
On a scale of 0 to 100, NextCure holds a performance score of 3. The company secures a Beta (Market Risk) of -0.35, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning NextCure are expected to decrease at a much lower rate. During the bear market, NextCure is likely to outperform the market. Please check NextCure's semi variance, as well as the relationship between the daily balance of power and price action indicator , to make a quick decision on whether NextCure's current price movements will revert.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in NextCure are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak basic indicators, NextCure exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 13.1 M |
NextCure Relative Risk vs. Return Landscape
If you would invest 64.00 in NextCure on March 15, 2025 and sell it today you would earn a total of 4.10 from holding NextCure or generate 6.41% return on investment over 90 days. NextCure is currently generating 0.3075% in daily expected returns and assumes 6.4882% risk (volatility on return distribution) over the 90 days horizon. In different words, 58% of stocks are less volatile than NextCure, and 94% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
NextCure Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for NextCure's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as NextCure, and traders can use it to determine the average amount a NextCure's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0474
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | NXTC | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.49 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.31 actual daily | 6 94% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average NextCure is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of NextCure by adding it to a well-diversified portfolio.
NextCure Fundamentals Growth
NextCure Stock prices reflect investors' perceptions of the future prospects and financial health of NextCure, and NextCure fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on NextCure Stock performance.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | (35.51 M) | ||||
| Shares Outstanding | 28.05 M | ||||
| Price To Earning | (25.44) X | ||||
| Price To Book | 0.27 X | ||||
| Price To Sales | 9.52 X | ||||
| EBITDA | (52.79 M) | ||||
| Cash And Equivalents | 185.49 M | ||||
| Cash Per Share | 6.68 X | ||||
| Total Debt | 5.95 M | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | 1.99 X | ||||
| Cash Flow From Operations | (40.8 M) | ||||
| Earnings Per Share | (1.98) X | ||||
| Total Asset | 80.86 M | ||||
| Retained Earnings | (380.14 M) | ||||
| Current Asset | 46.99 M | ||||
| Current Liabilities | 5.53 M | ||||
About NextCure Performance
By analyzing NextCure's fundamental ratios, stakeholders can gain valuable insights into NextCure's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if NextCure has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if NextCure has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Nextcure operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 87 people.Things to note about NextCure performance evaluation
Checking the ongoing alerts about NextCure for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for NextCure help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| NextCure had very high historical volatility over the last 90 days | |
| NextCure has some characteristics of a very speculative penny stock | |
| NextCure has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (55.65 M) with loss before overhead, payroll, taxes, and interest of (54.2 M). | |
| NextCure currently holds about 185.49 M in cash with (40.8 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| NextCure has a poor financial position based on the latest SEC disclosures |
- Analyzing NextCure's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether NextCure's stock is overvalued or undervalued compared to its peers.
- Examining NextCure's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating NextCure's management team can have a significant impact on its success or failure. Reviewing the track record and experience of NextCure's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of NextCure's stock. These opinions can provide insight into NextCure's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for NextCure Stock analysis
When running NextCure's price analysis, check to measure NextCure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NextCure is operating at the current time. Most of NextCure's value examination focuses on studying past and present price action to predict the probability of NextCure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NextCure's price. Additionally, you may evaluate how the addition of NextCure to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |